Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Risk Of Hepatotoxicity In Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review And Meta‐analysis Of Published Data

Wenjun Wang, puyi Lie, Minzhang Guo, J. He
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Although existing evidence from clinical trials has demonstrated manifestation of hepatic adverse events with the use of immune checkpoint inhibitors (ICPIs), overall risks have yet to be reported. Therefore, we assessed the risk of hepatotoxicity associated with inhibitors of the immune checkpoint. We examined data from the Pubmed, Medline and Google Scholar databases. We also examined original studies and review articles for crossreferences Eligible studies included randomized Phase II to Phase III trials of cancer patients treated with nivolumab, pembrolizumab, ipilimumab, tremelimumab. The authors extracted relevant information on participants' characteristics, all‐grade and high‐grade hepatotoxicity and information on the methodology of the studies. In total, 17 trials were considered eligible for the meta‐analysis. The odds ratio for all‐grade hepatotoxicity for CTLA‐4 inhibitors (Ipilimumab and tremelimumab) was 1.24 (95% confidence interval 0.75, 2.05; p = 0.39) and for high‐grade hepatotoxicity was 1.93 (95% confidence interval 0.84, 4.44; p =0.12). Moreover, the odds ratio for all‐grade hepatotoxicity for PD‐1 inhibitors was 1.52 (95% confidence interval 1.24, 1.86; p < 0.0001) and for high‐grade hepatotoxicity was 0.48 (95% confidence interval 0.29, 0.80; p =0.005). The analysis of data showed that CTLA‐4 inhibitors seem to be associated with a higher risk of all‐ and high‐grade hepatotoxicity compared with control regimens, whereas PD‐1 inhibitors seem to be associated with a lower risk of all‐ and high‐grade hepatotoxicity compared with control regimens.
This paper references
10.1016/S1470-2045(15)70122-1
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
A. Eggermont (2015)
10.2307/2533446
Operating characteristics of a rank correlation test for publication bias.
C. Begg (1994)
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
10.1136/bmj.315.7109.629
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
10.2307/3001666
The combination of estimates from different experiments.
W. Cochran (1954)
10.1038/nrc3153
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
P. Sharma (2011)
Enhance - ment of antitumor immunity by CTLA - 4 block
DR Leach (1996)
10.1158/1078-0432.CCR-14-1187
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
V. Anagnostou (2015)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1016/S0140-6736(15)01281-7
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
10.1016/S1470-2045(13)70551-5
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
J. Westin (2014)
10.1200/JCO.2012.44.6112
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
a multicentre, randomised,doubleblind, phase 3 trial
CG Kwon ED Drake (2017)
10.1517/14740338.2015.1085969
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
O. Abdel-Rahman (2015)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1200/JCO.2011.38.4032
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.2217/imt.15.87
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
O. Abdel-Rahman (2015)
10.1093/annonc/mds213
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M. Reck (2013)
10.2217/fon.15.222
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
O. Abdel-Rahman (2016)
10.1016/S1470-2045(16)30098-5
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
S. Antonia (2016)
10.1016/S1470-2045(14)70189-5
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
J. Higgins (2003)
10.1016/S1470-2045(15)00083-2
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1089/cbr.2010.0865
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
A. Tarhini (2010)
10.1200/JCO.2013.53.4495
Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.
J. Bower (2014)
10.1053/j.seminoncol.2010.09.007
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
A. M. Di Giacomo (2010)
10.1093/annonc/mdw141
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J. Naidoo (2016)
10.1056/NEJMoa1414428
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
10.1056/NEJMc1509660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
M. Valsecchi (2015)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)



This paper is referenced by
10.1002/hep4.1503
Drug‐Induced Liver Injury in GI Practice
N. Sandhu (2020)
10.1136/bmj.k4226
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
C. Xu (2018)
10.1016/j.dld.2019.06.017
Hepatotoxicity of immune check point inhibitors: Approach and management.
A. Lleo (2019)
10.1186/s12885-019-5785-z
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Lihu Gu (2019)
10.1016/j.gastrohep.2020.07.009
Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional
Patricia Sanz-Segura (2020)
10.1016/j.jhep.2019.02.014
EASL Clinical Practice Guidelines: Drug-induced liver injury.
R. Andrade (2019)
10.1016/j.cld.2017.06.003
The Liver in Oncology.
R. Dhanasekaran (2017)
10.14735/amko2019133
Hepatic Injury Induced by a Single Dose of Nivolumab - a Case Report and Literature Review.
J. Kopecký (2019)
10.1117/12.2509371
Predicting treatment outcome and enhancing immunotherapy with anti-PDL1 gold nanoparticles
R. Meir (2019)
10.1159/000507695
Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
Thuridur Thorsteinsdottir (2020)
10.1111/1759-7714.13338
Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
Y. Li (2020)
10.4110/in.2020.20.e9
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
J. Choi (2020)
10.1016/j.rmcr.2020.101197
A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
Ryunosuke Ooi (2020)
10.1007/s00228-020-02903-2
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Xiao-di Guo (2020)
10.1159/000486679
Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients
Kevin Zarrabi (2018)
10.1136/flgastro-2018-101146
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
V. T. Cheung (2019)
10.1016/j.ygyno.2018.10.008
Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
E. Hinchcliff (2018)
10.1002/hep.31089
Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma
Laura Stuart (2019)
10.5858/arpa.2020-0070-RA
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy.
P. Patil (2020)
10.1177/1078155219837342
Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor
Vinay Mathew Thomas (2019)
10.1007/978-3-319-46029-1_60-1
Managing Checkpoint Inhibitor Symptoms and Toxicity
A. Pavlick (2019)
10.1016/j.critrevonc.2020.103167
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
E. Lai (2020)
10.1007/s11523-019-00632-w
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
E. Raschi (2019)
10.12968/hmed.2018.79.7.372
Managing side effects of cancer immunotherapy for the acute physician.
Benjamin A Pickwell-Smith (2018)
10.1136/esmoopen-2017-000268
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
G. Doherty (2017)
10.2177/jsci.40.102
Immune-related adverse events of immune checkpoint inhibitors.
Hiroki Tadano (2017)
10.1002/ijc.32145
Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer
Y. Liu (2019)
10.1016/j.humpath.2019.10.007
Something old, something new: liver injury associated with Total parenteral nutrition therapy and immune checkpoint inhibitors.
Cherise Meyerson (2019)
10.1016/j.mpdhp.2020.11.002
Pathology of immune checkpoint inhibitor-induced injury of the gastrointestinal tract and hepatobiliary system
Kshitij S. Arora (2020)
10.1038/s41571-019-0218-0
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F. Martins (2019)
10.1007/s11901-018-0408-8
Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease
D. Chascsa (2018)
10.1016/j.ejca.2019.09.022
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
A. Vozy (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar